SCHEMBL200594

SCHEMBL200594

CC(=O)SSc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.50
HSD17B10 Q99714 3/20 0.50
MAPT P10636 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
MGLL Q99685 1/20 0.50
ALDH1A1 P00352 3/20 0.47
FFAR1 O14842 1/20 0.41
MTNR1A P48039 4/20 0.41
MTNR1B P49286 4/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
NAPRT Q6XQN6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3766616 0.80 HPGD (0.55) HPGDHSD17B10MAPTSMN1; SMN2MGLL
SCHEMBL8508100 0.79 HPGD (0.42) HPGDHSD17B10MAPTSMN1; SMN2MGLL
SCHEMBL11874395 0.78 HPGD (0.52) HPGDHSD17B10MAPTSMN1; SMN2MGLL
SCHEMBL28144870 0.76 MAPT (0.50) HPGDHSD17B10MAPTSMN1; SMN2MGLL
SCHEMBL11615005 0.76 HSD17B10 (0.50) HPGDHSD17B10MAPTSMN1; SMN2MGLL
SCHEMBL342299 0.75 CA12 (0.54) HPGDHSD17B10MAPTSMN1; SMN2MGLL
SCHEMBL4183717 0.74 HPGD (0.48) HPGDHSD17B10MAPTSMN1; SMN2MGLL
SCHEMBL11621561 0.74 HPGD (0.48) HPGDHSD17B10MAPTSMN1; SMN2MGLL
Acetophenone SCHEMBL28222172 0.74 HPGD (0.67) HPGDHSD17B10MAPTSMN1; SMN2MGLL
Urea SCHEMBL27863158 0.72 HPGD (0.67) HPGDHSD17B10MAPTSMN1; SMN2MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1625 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4725949-A1 IMPROVED SOLID-PHASE PHOSPHORAMIDITE-SYNTHESIS OF LONG OLIGONUCLEOTIDE MOLECULES BioSpring Gesellschaft für Biotechnologie mbH (DE) 2026-04-15 EP claimed
EP-4725950-A1 IMPROVED SOLID-PHASE PHOSPHORAMIDITE-SYNTHESIS OF LONG OLIGONUCLEOTIDE MOLECULES BioSpring Gesellschaft für Biotechnologie mbH (DE) 2026-04-15 EP claimed
US-20260097383-A1 SOLID-PHASE PHOSPHORAMIDITE-SYNTHESIS OF LONG OLIGONUCLEOTIDE MOLECULES BioSpring Gesellschaft für Biotechnologie mbH (DE) 2026-04-09 US claimed
US-12492220-B2 Method for the preparation of oligonucleotides THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2025-12-09 US claimed
US-12435105-B2 Technologies for oligonucleotide preparation WAVE LIFE SCIENCES LTD. (SG) 2025-10-07 US claimed
US-12264174-B2 Process for preparing imetelstat GERON CORPORATION (US) 2025-04-01 US claimed
EP-4526944-A1 THTOCARBONATE COMPOSITIONS FOR LITHIUM- SULFUR BATTERIES Conamix Inc. (US) 2025-03-26 EP claimed
CN-113631564-B Method for producing oligonucleotide having phosphorothioate site 味之素株式会社 2025-02-25 CN claimed
CN-114573652-B Process for synthesizing medicinal nucleic acid 安徽瑞拜药业有限公司 2025-02-07 CN claimed
EP-3475292-B1 SYNTHESIS OF THIOLATED OLIGONUCLEOTIDES WITHOUT A CAPPING STEP BIOGEN MA INC (US) 2024-09-18 EP claimed
EP-1386925-A1 Method for preparing oligonucleotides Girindus AG (DE) 2004-02-04 EP claimed
US-20030212267-A1 Synthesis of sulfurized oligonucleotides IONIS PHARMACEUTICALS, INC. 2003-11-13 US claimed
EP-1246833-A4 IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS INC (US) 2003-04-09 EP claimed
EP-1246833-A1 IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 2002-10-09 EP claimed
WO-2001051502-A1 IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 2001-07-19 WO claimed
US-6242591-B1 Synthesis of sulfurized 2'-substituted oligonucleotides ISIS PHARMACEUTICALS, INC. 2001-06-05 US claimed
EP-1023310-A4 IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS INC (US) 2001-05-16 EP claimed
US-6114519-A PHOSPHITYLATION; OXIDATION ACYL DISULFIDE ISIS PHARMACEUTICALS, INC. (US) 2000-09-05 US claimed
EP-1023310-A1 IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 2000-08-02 EP claimed
WO-1999019340-A1 IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 1999-04-22 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260097383-A1 SOLID-PHASE PHOSPHORAMIDITE-SYNTHESIS OF LONG OLIGONUCLEOTIDE MOLECULES RNGTT, NSUN2, RNMT HPGD 4835/4885HSD17B10 4511/4885MAPT 3290/4885
US-12435105-B2 Technologies for oligonucleotide preparation POLRMT, DCLRE1B, RNGTT HPGD 4878/4885HSD17B10 3496/4885MAPT 1403/4885
US-12492220-B2 Method for the preparation of oligonucleotides POLN, POLRMT, POLI HPGD 4026/4885HSD17B10 4366/4885MAPT 3637/4885
US-12264174-B2 Process for preparing imetelstat TERT, RNGTT, TRMT1L HPGD 3465/4885HSD17B10 2985/4885MAPT 1169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.